Company: SXTPW
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-043779
Chunk: 171

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 2
Chunk 171
---
1,740,847 for the three months ended March
31, 2024. During the periods presented, derivative liabilities include the contingent milestone payment due to Knight upon a future sale
of Arakoda or a Change of Control. We use a probability-weighted expected return method to estimate the fair value of this derivative
liability.

Other Income, net 

For the three months ended March 31, 2025, we recognized $30,322 in
other income compared to $31,051 for the three months ended March 31, 2024. For the three months ended March 31, 2025, we recognized interest
income from cash invested in interest-bearing accounts and investments in certificates of deposit of $31,897 ($21,888 for the three months
ended March 31, 2024). Other income for the three months ended March 31, 2024 also includes $10,789 of storage revenue recognized in association
with final payment under the legacy contract with the USAMMDA for storing Arakoda purchases. We did not recognize storage revenue for
the three months ended March 31, 2025.

Cash Flows

    For the Three Months Ended March 31,  

    2025  
    2024  
    $ Change  
    % Change 
  
    Net Cash (Used In) Provided By : 

    Operating Activities 
    $(1,597,366) 
    $(1,140,438) 
    $(456,928) 
     40.07%
  
    Investing Activities 
     1,702,518  
     (9,814) 
     1,712,332  
     (17,447.85)
  
    Financing Activities 
     1,696,899  
     1,903,291  
     (206,392) 
     (10.84)
  
    Effect of Foreign Currency Translation on Cash Flow 
     (9,904) 
     (824) 
     (9,080) 
     1,101.94 
  
    Net Increase in Cash and Cash Equivalents 
    $1,792,147  
    $752,215  
    $1,039,932  
     138.25%

31

Cash Used in Operating Activities

Net cash used in operating activities was $1,597,366 for the three
months ended March